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ABSTRACT
Alternative splicing of fibroblast growth factor
receptor-2 (FGFR2) mutually exclusive exons
IIIb and IIIc results in highly cell-type-specific expres-
sionoffunctionallydistinctreceptors,FGFR2-IIIband
FGFR2-IIIc. We previously identified an RNA cis-
element, ISE/ISS-3, that enhanced exon IIIb splicing
and silenced exon IIIc splicing. Here, we have per-
formed comprehensive mutational analysis to
define critical sequence motifs within this element
that independently either enhance splicing of
upstream exons or repress splicing of down-
stream exons. Such analysis included use of a
novel fluorescence-based splicing reporter assay
that allowed quantitative determination of
relative functional activity of ISE/ISS-3 mutants
using flow cytometric analysis of live cells. We
determined that specific sequences within this
element that mediate splicing enhancement also
mediate splicing repression, depending on their
position relative to a regulated exon. Thus, factors
that bind the element are likely to be coordinately
involved in mediating both aspects of splicing
regulation. Exon IIIc silencing is dependent upon a
suboptimal branchpoint sequence containing a
guanine branchpoint nucleotide. Previous studies
of exon IIIc splicing in HeLa nuclear extracts demon-
strated that this guanine branchsite primarily
impaired the second step of splicing suggesting
that ISE/ISS-3 may block exon IIIc inclusion at this
step. However, results presented here that include
use of newly developed in vitro splicing assays of
FGFR2 using extracts from a cell line expressing
FGFR2-IIIb strongly suggest that cell-type-specific
silencing of exon IIIc occurs at or prior to the first
step of splicing.
INTRODUCTION
Alternative splicing represents an important mechanism used
by the cell to generate multiple transcripts from a single gene
and at least 60% of genes appear to generate more than one
spliced mRNA (1–3). Despite growing appreciation of the
relevance of alternative splicing to normal development as
well as its role in disease, the molecular mechanisms that
control this process in mammalian cells are poorly understood.
A general model of splicing regulation has emerged whereby
splicing regulatory factors inﬂuence the ability of the basal
splicing machinery to recognize consensus sequence elements
present at exon/intron (the 50 splice site) and intron/exon
boundaries (the 30 splice site) (1,4). The 30 splice site consists
of an invariant AG at the end of the intron and a polypyrimi-
dinetract (PPT)locatedupstreamfromit.UpstreamofthePPT
is the branchpoint sequence (BPS) that is also involved in
recognition of the 30 splice site. Together, these consensus
sequences are required for recruitment of the spliceosome,
the macromolecular machine that performs the catalytic
steps of splicing (5). The spliceosome consists of ﬁve small
nuclear ribonucleoprotein particles, U1, U2, U4, U5 and U6,
which, together with numerous additional constitutive splicing
factors, assemble in a stepwise fashion at the splice sites. The
initial steps include binding of U1 at the 50 splice site, U2-
auxiliary factor 65 and 35 kDa subunits (U2AF65 and
U2AF35) to the PPT and 30 splice site, and splicing factor 1/
branchpoint bridging protein (SF1/mBBP) to the branch-
point. Subsequently, U2 is recruited to the branchpoint, fol-
lowed by addition of U4, U5 and U6. After several structural
rearrangements, the two catalytic steps of splicing are carried
out.In the ﬁrst catalytic step, abranchpointnucleotide (usually
adenine) carries out a nucleophilic attack at the 50 end of the
intron to yield a branch structure containing a 20–50 phospho-
diester bond between the branchpoint nucleotide and the gua-
nine residue at the 50 end of the intron. In the second catalytic
step, the upstream exon is ligated to the 30 exon with release of
the intron as a branched intron. For both constitutive and
alternatively spliced exons and introns, the degree to which
the splice sites match the consensus sequences determines
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(including the BPS) are often described as being ‘strong’ or
‘weak’ depending on their conformity to the consensus, which
is presumed to reﬂect their inherent ability to recruit the
spliceosome.
In addition to the splice site consensus sequences, the pat-
tern of splicing is further inﬂuenced by auxiliary cis-elements
referred to as exonic or intronic splicing enhancers (ESEs or
ISEs) and exonic or intronic splicing silencers (ESSs or ISSs).
The exonic elements (ESEs and ESSs) have been shown to
play a signiﬁcant role in the splicing of both constitutively and
alternatively spliced exons (6). In contrast, while intronic ele-
ments (ISEs and ISSs) have been shown to inﬂuence the splic-
ing of some constitutive exons, they have predominantly
been described in regulation of alternatively spliced exons (7).
The important role that intronic sequences play in alternative
splicing is further highlighted by the fact that intron sequences
ﬂanking alternatively spliced exons (exclusive of the splice
sites) are more highly conserved phylogenetically than those
ﬂanking constitutively spliced exons (8,9). The functions of
many auxiliary cis-elements are mediated by splicing regula-
tory proteins that bind these elements and facilitate or prevent
splicing at nearby splice sites. Thus, strong phylogenetic
conservation of intronic sequences ﬂanking alternative
exons ispresumed toreﬂectsequence-speciﬁcbindingof regu-
latory factors that are involved in conserved alternative splic-
ing events. Frequently, multiple auxiliary cis-elements are
present within or ﬂanking alternatively spliced exons and posi-
tively or negatively inﬂuence splice site recognition. Such
observations have led to models of combinatorial control
whereby the splicing outcome is determined by the net
activity of several splicing regulatory factors that bind these
elements (1,10).
We have been studying the mechanisms that lead to cell-
type-speciﬁc splicing of two mutually exclusive exons, IIIb
and IIIc, in the ﬁbroblast growth factor receptor-2 (FGFR2)
transcript (Figure 1A). These exons encode two different pep-
tide sequences in the extracellular portion of the receptor
yielding two different isoforms, FGFR2-IIIb and FGFR2-
IIIc, with distinctly different ligand binding preferences.
Expression of FGFR2-IIIb is generally restricted to epithelial
cells and FGFR2-IIIc to mesenchymal cells and disruption of
the cell-type-speciﬁc splicing pattern of FGFR2 has been
implicated as one event that can play a role in cancer progres-
sion, including prostate cancer (11–13). Previous studies
by our laboratory and others have identiﬁed several auxiliary
Figure 1. Multiple auxiliary cis-elementsregulatesplicing of FGFR2mutuallyexclusive exons IIIb and IIIc. (A) Schematicrepresentation of the pre-mRNAin the
region containing exons IIIb and IIIc. Exons are indicated by shaded boxes and auxiliary cis-elements by hatched boxes. UISS and DISS indicate upstream and
downstream intronicsplicingsilencers,respectively. ESE, exonicsplicingsilencer. ISE,intronicsplicingenhancer. ISAR,intronicsplicing activator and repressor.
UGCAUG,sequencemotifthatalsofunctionsasanISEforexonIIIb.ThelocationsofFGFR2introns7,8and9areindicatedbybrackets.(B)AlignmentofISE/ISS-3
sequences from the indicated mammalian FGFR2 genes.
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sion of either exon IIIb or IIIc and are summarized in
Figure 1A. While RNA binding proteins that interact with
several of these elements have been identiﬁed, these proteins
have not revealed cell-type-speciﬁc differences in expression
between cells that include exon IIIb or exon IIIc and thus the
mechanism by which cell-type-speciﬁc splicing is achieved
remains unclear (14–18). We recently identiﬁed ISE/ISS-3
(Intronic Splicing Enhancer/Intronic Splicing Silencer-3), so
named because its deletion led to loss of cell-type-speciﬁc
enhancement of exon IIIb as well as loss of exon IIIc repres-
sion in cells that express FGFR2-IIIb (19). However, it
remained unclear whether the ISE and ISS activities we
described were carried out by distinct sequences within the
element, or whether the same sequences are involved in both
activities. Through systematic mutational analysis of ISS/
ISE-3 we have now determined that sequences that are critical
for activation of an upstream exon are also involved in silenc-
ing of a downstream exon.
We previously demonstrated that the ability of ISE/ISS-3 to
silence exon IIIc was facilitated by a highly atypical use of
guanine as the primary branch nucleotide. Because guanine as
a branch nucleotide was shown to impair the second step of
splicing more than the ﬁrst step of splicing in HeLa nuclear
extracts, we previously hypothesized that exon IIIc silencing
may be regulated at the second catalytic step. However, using
a newly developed in vitro splicing system from a cell type
that expresses FGFR2-IIIb, we show here that the ability of
different branch nucleotides to carry out exon IIIc splicing
in vivo correlates with their efﬁciency in carrying out the
ﬁrst step of splicing in vitro. Furthermore, cell-type-speciﬁc
exon IIIc silencing does not absolutely require a guanine as
the branch nucleotide as a consensus BPS containing
adenine as the branch nucleotide can also result in exon
IIIc silencing when accompanied by detrimental PPT muta-
tions. Therefore, exon IIIc silencing involving ISE/ISS-3 pre-
vents use of its associated 30 splice site at or prior to the ﬁrst
step of splicing.
MATERIALS AND METHODS
Plasmid construction
All minigenes were made using standard cloning techniques.
pI-11-FS-CXS, pI-11-FS-CXS-IIIb Mut, pI-XN-33.51-IF5,
pI-11-FS and pI-11(-H3)PL-3CT constructs were described
previously (19). The ISE/ISS-3 fragment presented in
Figure 2B and C and Figure 4 was a 105 nt insert obtained
by PCR of pI-11-FS with ISE3-Cla-F2 (50-CATCGATGTGT-
GGTGATGGGCCTGCAG-30) and ISE3-Xho-R4 (50-CTCG-
AGGTGCTGGCCATCAGGAGATT-30)primersandinsertion
into the ClaI/XhoI sites of the indicated minigenes. The ISE/
ISS-3 element presented in all other ﬁgures consisting of the
85 nt sequence element shown in Figure 2A was made by PCR
ampliﬁcation of pI-11-FS with primers ISE-3-Cla-F2 and
ISE3-Xho-R5 (50-CTCGAGCCAACTGCAGCCCGTCCAC-
A-30). The difference between these inserts is a non-
functional 20 nt at the 30 end of the 105 nt element. All
ISE/ISS-3 mutations and the PPT mutations were introduced
using PCR-based oligonucleotide-mediated mutagenesis. The
control BG fragment (105 nt) was obtained by PCR of the
second intron of human b-globin gene with BG-105-F
(50-CCGGGCGGCCGCTATACTTAATGCCTTAACAT-30)
and BG-105-R (50-CCGCATCGATGATTGTAGCTGCTAT-
TAGCA-30) primers. The control BS fragment (85 nt) was
made by PCR of pBlueScript (Stratagene) with primers
BS85-Cla-F (50-CATCGATTCTACACGACGGGGAGTC-
AG-30) and BS85-Xho-R (50-CTCGAGTACCAATGCTTAA-
TCAGTGA-30). To generate the ﬂuorescent minigene
PKC-neg-33.51-IF-5-EGFP we ﬁrst modiﬁed pIRESneo3
(Clontech) by removing the synthetic intron. A sequence con-
taining a 50 exon derived from the rat protein kinase C-g
subunit coding sequence, an adenoviral intron from pI-11
(20), and a 50 exon derived from the coding sequence of
EGFP was then inserted into the NheI and NotI sites in the
modiﬁed pIRESneo3 vector to generate PKC-neg-EGFP. The
enhanced green ﬂuorescent protein (EGFP) sequence was
modiﬁed by replacing the ATG at the 50 end of the coding
sequence with ATC, and a linker sequence 50-GCTTAAT-
TAAT-30 was inserted between this substituted codon and
the 30 splice site of the upstream intron. PKC-neg-33.51-IF-5-
EGFP was then generated by inserting the 33.51 exon and
ﬂanking intron sequences in the BamH1 and XhoI sites in
the intron of PKC-neg-EGFP (further details available on
request). Derivative plasmids shown in Figure 3 were gener-
ated by inserting ISE/ISS-3 or mutant controls between the
ClaI and XhoI sites. pI-11(-H3)-D1, pI-11(-H3)-D2, pI-11
(-H3)-D3 and pI-11(-H3)-D4 minigenes were made by ﬁrst
using PCR of pI-11-FS-CXS with forward primers Intron-
2F (50-CCGGACTAGTCAACGTTTTTGTGTTTGTGT-30),
IAS2-F-Spe (50-ACTAGTTGGCCATGGAAAAATGCC-
CA-30), 3Cplus-F-Spe (50-ACTAGTTGTGGGCTGATT-
TTTCCATG-30) and 3Cminus-F-Spe (50-ACTAGTATCGA-
TGTGTGGTGATGGGC-30), respectively, and the reverse
primer Int-3CR-Sal (50-GTCGACGGTCGGAAATCATTC-
GAAAC-30) followed by cloning into the XbaI and XhoI
sites of pI-11(-H3)-PL (19). ISE/ISS-3, Mut 13 and BG
were subsequently inserted into the ClaI/XhoI sites of the
respective minigenes as shown in Figure 4. The branchpoint
mutations were introduced using the QuikChange Kit (Strata-
gene). All plasmid constructs were prepared with Qiagen
MidiPrep kits. Sequences of all the minigenes described
were conﬁrmed by sequence analysis by the University of
Pennsylvania Sequencing Facility.
Transfections, RNA purification and splicing analysis
Transfection of DT3and AT3 cells, RNA puriﬁcation and RT–
PCR analysis of minigene splicing were performed as
described previously (19). Data quantiﬁcation was performed
using a Molecular Dynamics PhosphorImager. Flow Cytome-
try was performed using a Becton Dickinson FACSCalibur
and analyzed with BD CellQuest Pro.
Extract preparation and in vitro splicing assays
HeLa and KATO III nuclear extracts were prepared as
described previously (21). KATO III cells were grown by
the National Cell Culture Center (Minneapolis, MN) and
shipped overnight on wet ice prior to extract preparation.
In vitro transcription of pre-mRNAs and in vitro splicing
was performed as described previously (19).
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Systematic mutational analysis identifies several critical
regulatory sequence elements within ISE/ISS-3
We have previously shown that ISE/ISS-3 plays a role in both
activation of exon IIIb splicing and silencing of exon IIIc
splicing in cell types that express FGFR2-IIIb from its position
in the intron (intron 8) located between these mutually exclu-
sive exons (19). Thus, deletion of ISE/ISS-3 independently
results in both loss of exon IIIb splicing activation and loss of
exon IIIc repressionin DT3 cells(that express FGFR2-IIIb). In
contrast, deletion of ISE/ISS-3 did not result in any change in
AT3 cells (that express FGFR2-IIIc), which maintained exclu-
sive inclusion of exon IIIc. We previously deﬁned a minimal
85 nt sequence that was sufﬁcient to carry out these regulatory
activities. This 85 nt sequence shows extensive phylogenetic
sequence conservation consistent with its critical role in splic-
ing regulation (8,9) (Figure 1B). In order to better characterize
speciﬁc sequences within ISE/ISS-3 that mediate FGFR2
splicing regulation we introduced a series of scanning muta-
tions by sequentially mutating blocks of 6 nt along the length
of the element (Figure 2A). Sequences containing the muta-
tions were initially inserted into an FGFR2 minigene, pI-11-
FS-CXS, in which ISE/ISS-3 had been deleted and replaced
withClaI andXhoI restrictionsites (Figure2B). This minigene
contains both exons IIIb and IIIc as well as all other known
regulatory cis-elements shown in Figure 1A. Plasmid mini-
gene constructs were generated containing the wild-type ISE/
ISS-3 element or ISE/ISS-3 elements containing each of
14 different mutations. These minigenes were transfected
Figure 2. Systematic mutational analysis of ISE/ISS-3 defines sequences that are critical for its function as an ISE and ISS. (A) The wild-type ISE/ISS sequence
is indicatedand14separatemutationsareindicatedaboveinitalicsandnumberedasindicatedbelowthewild-typesequence.Thewild-typeandmutatedISE/ISS-3
sequences(orunrelatedcontrolBGorBSsequences)wereclonedbetweenClaIandXhoIsitesintheminigenesshowninB,CandDandtheresultingminigeneswere
stablytransfectedinDT3cells.(B)ResultsofthemutationsonexonIIIbandIIIcsplicinginthepI-11-FS-CXSminigene.‘A’indicatedminigeneswithoutISE/ISS-3
and‘B’indicatesminigeneswithwild-typeISE/ISS-3insertedandactualRT–PCRresultsfortheseminigenesareshownatfarright(thesesamedesignationsapplyto
C and D). The graph represents percentage of spliced minigene products containing exon IIIb. Determination of products containing exon IIIb or exon IIIc was
determined by digestion of the RT–PCR products with endonucleases AvaI or HincII, which digest products containing exon IIIb and IIIc, respectively. Exon IIIb
inclusionisthereforecalculatedastheamountofRT–PCRproductremainingafterHincIIdigestiondividedbythesumofthatremainingafterbothAvaIandHincII
digestion. U(above lanes 1 and 4), undigestedproducts;A, AvaI digestedproducts;H, HincII digested products.(Note: we also observea small fractionof products
containingbothexonsIIIbandIIIcaswellasthoseinwhichbothexonsareskipped,buttheseproductsarenotconsideredhere).(C)Resultsofmutationsoninclusion
oftheupstreamexon33.51inminigenepI-XN-33.51-IF5.Hereanasteriskisusedtoindicatethatapartiallytruncatedsequencederivedfromintron8containingall
theshowncis-elementswasusedintheheterologousminigene.ArepresentativeRT–PCRisshownatrightandthepercentageexon33.51forallmutationsisshown
graphically. (D) Results of mutations on skipping of exon IIIc in minigene pI-11-FS-CXS-IIIb-Mut. The schematic at left indicates mutations in the 30 and 50 splice
sites of exon IIIb. BG and BS represent size-matched unrelated control sequences derived from human b-Globin and pBluescript, respectively. U and D in the
schematicsrepresentupstreamanddownstreamadenoviralexonspresentineachminigene.Inthisandsubsequentfigures,experimentswereperformedintriplicate
and error bars indicate SD.
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with the minigenes were used to harvest RNA and the levels of
exon IIIb or IIIc splicing were determined using a previously
validated RT–PCR assay (see Figure 2B, far right) (19,20,22).
As an additional control we also inserted a size-matched
sequence derived from a b-globin intron. In the absence of
ISE/ISS-3, we noted that only 25% of spliced products con-
tained exon IIIb in DT3 cells; thus, 75% of spliced products
instead contained exon IIIc (Figure 2B, lane A). When the
wild-type ISE/ISS-3 element is inserted back in its normal
position in intron 8, splicing of exon IIIb is restored with 81%
of products now splicing exon IIIb in preference to exon IIIc
(Figure 2B, lane B). In AT3 cells, there was no difference in
splicing of minigenes containing ISE/ISS-3 or in which it was
deleted; they included almost exclusively products containing
exon IIIc (data not shown). For these two minigenes, the actual
RT–PCR data are shown at far right and data for all mutations
arepresentedgraphicallyinthemiddle(Figure2B).Thus,ISE/
ISS-3 functions in a cell-type-speciﬁc manner to promote
splicing of exon IIIb in favor of exon IIIc (19). When the
results of the mutations of ISE/ISS-3 on exon IIIb splicing
in DT3 cells were analyzed, we noted that seven mutations
(Mut 1, Mut 2, Mut 4, Mut 6, Mut 9, Mut 11 and Mut 13)
resulted in a >25% reduction in exon IIIb inclusion compared
with the wild-type element (Figure 2C). In contrast, the other
seven mutations resulted in lesser degrees of impairment
Figure 3. Fluorescent reporter minigenes facilitate identification of GU-rich sequences in the 50 half of ISE/ISS-3 as most critical for its function. (A) ISE/ISS-3
with GU or UG dinucleotides that were mutated in bold and underlined. The 50 and 30 sequences are indicated by the dashed line and a single GU to AC mutation is
indicated(GUMut).(B)SchematicoftheFluorescentminigenedevelopedforanalysisofISE/ISS-3function.(C)ResultsofRT–PCRinDT3cellsstablytransfected
withtherespectiveminigenes.ThefluorescentminigenePKC-neg-EGFPcontainingnointernal33.51exon(Dexon33.51)isshowninlane1.Lanes2and3represent
results in which ISE/ISS-3 is absent or present downstream of exon 33.51, respectively. Lanes 4–9 indicate minigenes in which the GU or UG dinucleotides have
beenchangedtoAC,GAorGCinthe50 or30 halfofISE/ISS-3.GUMutrepresentsaminigenewiththesingleGUtoACmutationandBSisthesize-matchedcontrol.
The value of 1.1% for lane 1 likely reflects background radioactivity detected by the phosphorimager given the absence of exon 33.51 in the minigene used.
(D)Graphicalpresentationofthe%exon33.51inclusionnormalizedtotheamountofexoninclusionobtainedwiththewild-typeISE-ISS-3,whichwasarbitrarilyset
at100%torepresentitscompleteactivity.Theresultswerethencalculatedforeachminigeneas(%exon33.51inclusion/%exon33.51inclusionwiththe minigene
containing ISE/ISS-3) · 100. The calculated relative values are indicated above each bar. Numbers are the same as the lanes in ‘C’ and in the graph in ‘F’.
(E)RepresentativeFlowCytometricAnalysisofpoolsofstablytransfectedDT3cells.Numberscorrespondtotheminigenesindicatedusedperlanenumbersin‘C’.
While only four minigenes are presented for clarity, these experiments were performed and analyzed in parallel with all of the minigenes represented in ‘F’.
(F)Graphicalpresentationofrelative%exon33.51ascalculatedusingMFIforthesameminigenesshowninCandD.SimilartothenormalizationusedinD,results
werecalculatedas(MFI/MFIwiththeminigenecontainingISE/ISS-3) · 100.Thesamesetofstabletransfectionswasindependentlyrepeatedwithnearlyidentical
results.
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several sequence motifs along the length of the element
are collectively required to mediate the role of ISE/ISS-3 in
maintaining FGFR2-IIIb expression. In addition, insertion
of the size-matched control BG sequence did not restore
exon IIIb splicing, further supporting a conclusion that speciﬁc
sequences of ISE-ISS-3 are required for FGFR2 splicing
regulation.
Figure 4. ISE/ISS-3 mediated silencing of exon IIIc does not require upstream intronic sequences. (A) Schematic representation of sequences tested for ability
to influence exon IIIc skipping. Sequences were amplified by PCR from pI-11-FS-CXS containing either wild-type ISE/ISS-3, mutation 13 (Mut 13) or
the control BG sequence. These sequences were then inserted in the intron of an adenoviral splicing construct. (B) Results of RT–PCR in DT3 cells
stably transfected with the indicated minigenes with successive truncation of intron 8 upstream of ISE/ISS-3. (C) Graphical representation of percentage exon
IIIc skipping.
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activation of an upstream exon also result in splicing
repression of a downstream exon
The fact that several of the mutations of ISE/ISS-3 result in a
partial switch from exon IIIb to exon IIIc splicing suggested
that they disrupt sequences required for exon IIIb activation,
exon IIIc repression or both. However, in the minigenes that
contain both exons IIIb and IIIc it is not possible to separately
examine the effect of each mutation on these two distinct
regulatory properties. We previously showed that the entire
ISE/ISS-3 element can independently activate exon IIIb as
well as repress exon IIIc in DT3 cells (19). However, it
remained possible that some sequences within ISE/ISS-3
could activate splicing of the upstream exon IIIb, while
other sequences are predominantly involved in repression of
the downstream exon IIIc. We therefore tested all of the muta-
tions in contexts in which these activation and repression
functions can be independently analyzed. To study activation
we used a previously described heterologous minigene, pI-
XN-33.51-IF5 in which we inserted ISE/ISS-3 downstream
of a troponin exon (exon 33.51) and determined the amount
of its inclusion versus skipping (Figure 2C). This heterologous
minigene also includes FGFR2 intron 8 cis-elements located
upstream of ISE/ISS-3 such that the context of its function
relative to the regulated exon is similar to that in its endoge-
nous position. To study repression we used a minigene, pI-11-
FS-CXS-IIIb-Mut, in which both the 30 and 50 splice sites
of exon IIIb are mutated to preclude exon IIIb splicing
(Figure 2D). We stably transfected DT3 cells with both
types of minigenes and determined the degree to which the
mutations inﬂuenced the ability of ISE/ISS-3 to enhance or
silence splicing of an upstream or downstream exon, respec-
tively. To simplify comparison we present the results for exon
IIIc repression as the percent of skipping (relative to exon IIIc
inclusion) and for activation as the percent troponin exon
inclusion (relative to skipping). As shown in Figure 2C and
D, it can be seen that the same mutations that caused a switch
from exon IIIb to IIIc splicing generally also affected both
splicing enhancement of an upstream exon as well as silencing
of a downstream exon, although there were some differences
in the relative degree to which the different mutations affected
each function. These results thus demonstrate that ISE/ISS-3 is
a distinct element with dual effects on splicing and thus does
not consist of separable elements that independently either
activate splicing of an upstream exon or repress splicing of
a downstream exon.
GU-rich sequences in the 50 end of ISE/ISS-3 constitute
the most important functional fragment of ISE/ISS-3 as
determined using a novel fluorescence-based splicing
assay
ISE/ISS-3 has a notably high GU content, with G or U com-
prising 74% of its nucleotides. We also noted that mutations
that impaired splicing regulation were somewhat more preva-
lent within a highly conserved stretch at the 50 end of the
element containing several GU or UG dinucleotides. We
mutated all GU or UG dinucleotides in either the 50 or 30 half
of ISE/ISS-3 to AC, GA or GC (Figure 3A). These mutations
were introduced in a modiﬁed version of the heterologous
minigene described previously (Figure 2C). In this minigene,
PKC-neg-33.51-IF-5-EGFP, a 50 terminal exon was substi-
tuted that consisted of a 159 nt open reading frame derived
from rat protein kinase C (PKC)-g containing an optimal
Kozak consensus sequence at the 50 end (Figure 3B). A 30
terminal exon was inserted that contained a coding sequence
for EGFP. The intron sequences and the exon 33.51 sequence
were unchanged from that of pI-XN-33.51-IF5 (Figure 2C).
The design of this minigene established an open reading frame
in the 50 exon that, when exon 33.51 was skipped (or not
present as in D exon 33.51), did not maintain an open reading
frame encoding EGFP. However, inclusion of the 46 nt exon
33.51 was predicted to restore a reading frame encoding an
EGFP fusion protein containing the PKC and exon 33.51
encoded amino acids at the 50 end. In addition, an Internal
Ribosome Entry Site (IRES) directing expression of a neomy-
cin selection cassette was present downstream of the EGFP
coding sequence. This design ensured that essentially all cells
that survived in selective media expressed the minigenes since
the minigene and the selectable marker were translated from a
single transcript.
Fluorescent minigenes containing wild-type or mutated
ISE/ISS-3 were stably transfected in DT3 cells and exon
33.51 inclusion was determined by RT–PCR. We again
observed minimal exon 33.51 inclusion in the absence of
ISE/ISS-3, but over 50% inclusion when it was present
(Figure 3C and D, lanes 2 and 3). We found that mutation
of all GU or UG dinucleotides in the 50 half of the element was
sufﬁcient to abolish ISE activity, whereas mutations in the 30
half only partially impaired its function (Figure 3C and D,
lanes 4–9). The fact that three different sequence replacements
achieved similar outcomes suggests that the reduction in exon
33.51 inclusion results from loss of sequences in ISE/ISS-3
that are critical for its function and is not due to the unintended
introduction of sequences that silence its splicing. Further-
more, these results suggest that the 50 end of ISE/ISS-3 is
required in order to enhance splicing of an upstream exon
whereas sequences in the 30 half of the element contribute,
but are less crucial. We also analyzed the same set of stably
transfected cells by ﬂow cytometry to determine whether the
level of green ﬂuorescence in pooled cells stably expressing
the minigene constructs was a reliable indicator of the level of
exon 33.51 splicing. Representative ﬂow cytometric analysis
using several minigenes is shown in Figure 3E to demonstrate
the ability to easily detect increased ﬂuorescence in response
to ISE/ISS-3 mediated enhancement of exon 33.51 inclusion.
To facilitate comparison of RT–PCR to mean ﬂuorescence
intensity (MFI) as a means of determining relative levels
exon 33.51 inclusion, we normalized the results for each
minigene to that obtained with the minigene containing
the wild-type ISE/ISS-3 element. When results from the
entire set of minigenes were examined, we observed an excel-
lent correlation between relative MFI by ﬂow cytometric anal-
ysis and exon 33.51 inclusion determined by RT–PCR
(Figure 3D and F, compare graphs). We observed no signiﬁ-
cant exon 33.51 inclusion and negligible ﬂuorescence in AT3
cells stably transfected with these same minigenes (data
not shown).
We used the same ﬂuorescence-based minigene construct to
screen a number of more discrete mutations in ISE/ISS-3 and
used ﬂow cytometric analysis to identify several mutations
that resulted in the greatest loss of exon 33.51 inclusion.
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cant impairment in ISE/ISS-3 function was a single substitu-
tion of an AC for a GU (Figure 3A, C–F, construct 10, Mut
GU). We noted that this mutation occurred within an 8 nt
sequence consisting entirely of Gs or Us that was completely
conserved among the species examined in Figure 1B, and
both mutations involving this region (Mut 1 and Mut 2)
impaired splicing regulation. Again, we noted a very tight
correlation between exon inclusion relative to the wild-type
element as determined by mean ﬂuorescence and RT–PCR.
ISE/ISS-3 can repress exon IIIc splicing independently
from upstream intron 8 elements
Previous results from analysis of the intron 8 elements that
activate splicing of exon IIIb suggested that the most robust
splicing activation involved the concerted action of several
elements in addition to ISE/ISS-3, including ISE-1, ISE-2,
ISAR and a UGCAUG sequence motif located between
ISAR and ISE/ISS-3 (19,23). To determine whether ISE/
ISS-3 mediated repression of exon IIIc requires cooperation
bythese upstream cis-elements, we made a series of minigenes
in which we sequentially shortened intron 8 upstream of ISE/
ISS-3 (Figure 4A). Into each of the resulting minigenes we
insertedthewild-typeISE/ISS-3,ISE/ISS-3 with Mut13orthe
unrelated BG control sequence. Results from transfection of
this series of minigenes in DT3 cells are shown in Figure 4B.
When all upstream elements as well as ISE/ISS-3 are present,
73% of the products skip exon IIIc (Figure 4B, lane 1). How-
ever, when ISE/ISS-3 contains mutation 13, exon IIIc skipping
is decreased (Figure 4B, lane 2). Complete replacement of
ISE/ISS-3 with the BS control sequence results in a greater
decrease in exon skipping to 38% (Figure 4B, lane 3). When
the sequences upstream of ISE/ISS-3 are progressively deleted
in the presence of the wild-type ISE/ISS-3 element a gradual
decrease in the amount of exon IIIc skipping was observed
(Figure 4B, lanes 4, 7 and 10). However, in each case the
ability of ISE/ISS-3 to promote exon IIIc skipping is preserved
as evidenced by the fact that exon skipping is signiﬁcantly
decreased when it is mutated or replaced. With minigene con-
struct D4, none of the intron 8 sequences upstream of ISE/ISS-
3, including the UGCAUG motif, is present, signifying that it
can function to silence exon IIIc in their absence. The fact that
exon IIIc skipping decreased with progressive truncation of
intron 8 from the 50 end could signify a sequence-dependent
contribution from upstream elements on exon IIIc repression.
However, this could also represent a non-speciﬁc effect due to
approximation of the upstream exon to the 30 splice site of
exon IIIc. Nonetheless, in each case the wild-type ISE/ISS-3
sequence was capable of repressing exon IIIc splicing in a
sequence-dependent manner. Therefore, we conclude that
the ISE/ISS-3 element can repress splicing of the downstream
exon IIIc independent of the other intron 8 elements described
here. It is noteworthy that the construct used to demonstrate
ISE/ISS-3 mediated activation of exon 33.51 splicing does not
contain any downstream FGFR2 sequences whereas the
D4 construct shown here to repress exon IIIc does not contain
any upstream FGFR2 sequences. Together, these results effec-
tively preclude the possibility that ISE/ISS-3 functions via an
RNA secondary structure with other sequences present in the
FGFR2 transcript, as was shown for ISE-2 and ISAR (22).
Therefore, it is assumed that the element is bound by regula-
tory trans-acting factors that play a role in splicing regulation.
Exon IIIc repression in DT3 cells is facilitated by a
suboptimal guanine branchpoint nucleotide
We previously mapped the branchpoint nucleotide used
during exon IIIc splicing by primer extension and determined
thattheprimarybranchnucleotideisaguanine(G)(19).Thisis
the only described example in which a G is used as the primary
branchnucleotide duringsplicingofamammalian pre-mRNA.
We showed that substitution of an adenine (A) in place of the
branchsite guanine upstream of exon IIIc abrogated the ability
of ISE/ISS-3 to repress exon IIIc splicing in DT3 cells with a
switch towardconstitutive inclusion of exon IIIc (19). Because
G was shown to inhibit the second step of splicing to a greater
degree than the ﬁrst step in vitro using HeLa cell nuclear
extracts, we hypothesized that repression of exon IIIc splicing
might occur during the second step of splicing (19,24).
Because cytosine (C) or uracil (U) branchpoints differentially
inhibit the ﬁrst and second step of splicing relative to the
preferred A, we sought to provide further evidence for or
against this hypothesis by directly comparing the efﬁciency
of exon IIIc repression using all four possible branch
nucleotides. The wild-type BPS used, CUAGC, is a perfect
match to the minimal mammalian branchpoint consensus,
CURAC, with the exception of G in place of the highly pre-
ferred A as the primary branch nucleotide (as indicated by the
underlined nucleotide). We generated minigenes in which we
replaced the G branch nucleotide with A, C or U and assessed
their ability to repress exon IIIc in transfected DT3 cells. In the
case of both the wild-type G branchpoint as well as when it is
substituted with A, we previously conﬁrmed experimentally
using in vitro splicing assays that the indicated branchpoint
nucleotides are indeed the predominant branch nucleophile
(19) (data not shown). Thus, we have every reason to believe
that this position withinthe overall BPS element represents the
branchpoint nucleotide with each of these substitutions. When
A was substituted, exon IIIc was included in over 94% of
spliced products (Figure 5B and C, lane 2). For this analysis,
we quantiﬁed exon IIIc inclusion to include the products con-
taining both exons IIIb and IIIc (‘double inclusion’) as well as
those only including exon IIIc. Products that skip exon IIIc
included those that only included exon IIIb or those that
skipped both exons. Note that, in contrast to previous ﬁgures
in which we presented exon IIIc skipping, we will henceforth
present levels ofexon IIIc inclusion. Relativeto useof Aas the
branch nucleotide, C had previously been shown to be less
efﬁcient during the ﬁrst step of splicing, but the second step of
splicing showed no impairment in HeLa nuclear extracts (24).
We thus reasoned that if substitution of a C as the branch
nucleotide also led to constitutive use of exon IIIc this
would be consistent with repression occurring at the second
step. However, substitution of a C did not result in constitutive
inclusion of exon IIIc, but instead exon IIIc silencing was still
achieved, although slightly more inclusion was seen than
occurred with G (Figure 5B and C, lane 3). Substitution of
U as the branch nucleotide resulted in even lower levels of
exon IIIc inclusion than occurred with G even though U was
previously shown to be less detrimental for completion of the
second step of splicing than G (Figure 5B and C, lane 4) (24).
380 Nucleic Acids Research, 2006, Vol. 34, No. 1Therefore, these results in vivo were not seemingly consistent
with the hypothesis that exon IIIc repression in DT3 cells
occurs during the second step of splicing.
The ability to silence exon IIIc with different
branchpoint nucleotides correlates with relative
efficiency with which the first step of exon IIIc splicing
occurs in vitro in nuclear extracts from a cell type that
expresses FGFR2-IIIb
Previously published relative efﬁciencies of the two steps of
splicing with all four branch nucleotides were determined
using pre-mRNA substrates unrelated to those described
here (24). Therefore, in order to further assess the effects of
the different branch nucleotides in a more relevant context we
determined their effects on splicing using pre-mRNAs con-
taining the 30 splice site of exon IIIc. The pre-mRNA we used
containedthe samesequences used inconstructD3asshownin
Figure 4A, but only contained sequences comprising the 50
half of exon IIIc. Thus, it contained ISE/ISS-3 as well as the
entire region encompassing the 30 splice site of exon IIIc. In
addition, we wished to determine the efﬁciencies of these steps
in nuclear extracts from a cell type that expresses FGFR2-IIIb
and which therefore would be predicted to repress exon IIIc
splicing. We have shown that transfection of our FGFR2 mini-
genes in HeLa cells results in exclusive exon IIIc splicing as
observed in AT3 cells (data not shown), indicating that HeLa
extracts would be unlikely to contain factors involved in exon
IIIc silencing. Although we were unable to generate splicing
competent nuclear extracts from DT3 cells, we have obtained
nuclear extracts from the human KATO III cell line that are
competent for in vitro splicing. Because KATO III cells
express endogenous FGFR2-IIIb and, similar to DT3 cells,
splice exon IIIb when transfected with our rat FGFR2 mini-
genes, extracts from these cells represent a more physiologic-
ally relevantsystem inwhich tostudy exon IIIcrepression(25)
(data not shown). We transcribed pre-mRNAs in vitro that
contained the wild-type G branch nucleotide as well as A,
C and U as was done in the transfected minigenes. In vitro
splicing reactions were carriedout in both HeLa and KATO III
nuclearextractsandthe efﬁciencyofbothstepsofsplicingwas
determined (Figure 6). As expected,in extracts from either cell
type, both steps of splicing were most efﬁcient when an ade-
nine residue was the branch nucleotide. In HeLa extracts, the
ﬁrst step was nearly as efﬁcient with G or C as the branch
nucleotide, and appeared somewhat less efﬁcient with U
(Figure 6B and D). However, in KATO III extracts, the
ﬁrst step of splicing was signiﬁcantly less efﬁcient with either
G or C relative to A and U resulted in the greatest impairment
(Figure 6C and E). Our observation that the ﬁrst step of splic-
ing to exon IIIc is least efﬁcient with U as the branch nucle-
otide contrasts with the previously cited work in which G
showed the lowest relative splicing efﬁciency for both steps
(24). Thus, it is clear that there are substrate and/or sequence-
context-dependent differences in the degree to which different
BPSs affect splicing. The relative rates of the second step of
splicing were similar in both cell types with an order of efﬁ-
ciency using each nucleotide being A>C>U>G. Thus, the
efﬁciency of the ﬁrst step of exon IIIc splicing in KATO
III extracts using each possible branchsite nucleotide corre-
lates directly with the degree to which exon IIIc splicing
Figure5.Substitutionofanadeninebranchsite,butnotacytosineoruracilbranchsite,abrogatesexonIIIcsilencinginDT3cells.(A)Schematicrepresentationofthe
branchsitesubstitutions in minigenepI-11-FS. A consensus adeninecontainingBPS is indicatedabove thewild-typeBPScontainingG.(B) ResultsofRT–PCRfor
minigenes containing each branchsite after stable transfection in DT3 cells. Right, possible splicing products with both IIIb and IIIc exons included (UBCD), with
eitherexonIIIb(UBD)orIIIc(UCD)includedandwithbothexonsIIIbandIIIcskipped(UD).(C)GraphicalrepresentationoftheRT–PCRdata.Thepercentageof
exon IIIc inclusion is calculated as the percentage of spliced products containing exon IIIc (UCD + UBCD)/(UCD + UBCD + UBD + UD) corrected for molar
equivalents.
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the greatest inhibition of the second step, exon IIIc repression
in DT3 cells is greater with U than it is with G. These results
are most consistent with a mechanism of exon IIIc silencing by
inhibition at or prior to the ﬁrst step of splicing.
Cell-type-specificISE/ISS-3mediatedrepressionofexon
IIIc in the presence of a consensus BPS can be restored
through mutations in the PPT
The highly uncommon use of G as the branch nucleotide
suggested that the mechanism of exon IIIc repression may
speciﬁcally require a weak branchpoint. The fact that substi-
tution of a consensus BPS abolished exon IIIc skipping in DT3
cells is consistent with this possibility. However, it is also
noteworthy that the PPT associated with the 30 splice site
of exon IIIc is very uridine rich, as has been shown to be
optimal for selection of a 30 splice site (26,27). The fact
that only 3 G residues interrupt a stretch of 25 pyrimidines
in this PPT indicates that it is a ‘strong’ cis-acting determinant
of exon IIIc splicing. In fact, numerous studies have indicated
that strong PPTs can compensate for weak BPSs, and vice
versa, suggesting that these two elements collectively con-
tribute to 30 splice site recognition (28). Thus, if an optimal
BPS is combined with the already optimal PPT the combined
‘strength’ of these signals may preclude exon silencing. To
further investigate whether exon IIIc silencing can only occur
with a weak branchpoint, we introduced mutations in the PPT
of exon IIIc and tested the effects of these mutations on exon
IIIc splicing. We substituted 3 guanine residues for 3 U resi-
dues in the PPT as shown in Figure 7A. These mutations were
introduced in the context of both the wild-type G branchpoint
Figure 6. Non-adenine branchsites primarily impair the first step of exon IIIc splicing in KATO III nuclear extracts. (A) Schematic representation of the in vitro
splicingconstruct.ExonIIIcwastruncatedandinsertedbetweenadenoviralexonstogetherwithupstreamintron8sequencescontainingISARandISE/ISS-3.Invitro
transcription with T7 polymerase was carried out after digestion of the plasmid template with ClaI. (B and C) In vitro splicing reactions with HeLa and KATO III
nuclearextracts,withpre-mRNAscontainingtheindicatedbranchnucleotides.Pre-mRNAswereincubatedinnuclearextractsintheabsenceofATP( ATP)orwith
ATP for the indicated time points. At right, icons indicate lariat intermediate (LI), lariat product (LP), pre-messenger RNA (pre-mRNA) and messenger (spliced)
RNA (mRNA). (D and E) Graphical representation of the efficiency of the first or second step of splicing. Calculation of the first step efficiency represents the
percentage of pre-mRNA processed to lariat intermediate or lariat product (LI + LP/LI + LP + pre-mRNA). The efficiency of the second step (after step one)
represents the percentage of products undergoing the first step that also completethe second step (LI/LI + LP). Results presented in D and E represent experiments
performed three times with averages and SD indicatedin the graphs. The different branchpoints are indicated as follows: A, triangles; G, squares; C, circles; and U,
diamonds.
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nucleotide. To simplify the analysis, we introduced these
mutations in the context of the pI-11-FS-CXS-IIIb-Mut mini-
genes to limit the analysis to exon IIIc inclusion. The resulting
minigenes, therefore, encompassed a spectrum in which both
the BPS and the PPT were ‘strong,’ either the BPS or the PPT
was ‘weak,’ or in which both were ‘weak’. We then further
tested each BPS/PPT combination when ISE/ISS-3 was
present, deleted or mutated with the single GU to AC mutation
described in Figure 3 (GU Mut). Consistent with our previous
results, when both the BPS and PPT were ‘optimal’ we noted
nearly constitutive levels of exon IIIc splicing in the presence
or absence of wild-type ISE/ISS-3; over 92% exon IIIc
inclusion was achieved in DT3 or AT3 cells, although there
was still a slightly decreased level with ISE/ISS-3 in DT3 cells
(Figure 7B and C, lanes 7–10). When the wild-type (subop-
timal) BPS and wild-type (optimal) PPT were used, ISE/ISS-3
resulted in a >2-fold decrease in exon inclusion in DT3 cells,
consistent with previous data (Figure 7B, lanes 1 and 2).
The GU to AC mutant resulted in a partial abrogation of
the ability of ISE/ISS-3 to repress exon IIIc, similar to its
ability to impair exon 33.51 activation (Figure 7B, lane 3).
Interestingly, the combination of an optimal BPS and a sub-
optimal PPT elicited results that were very similar to those
with the opposite combination; ISE/ISS-3 caused a >2-fold
decrease in exon IIIc inclusion in DT3 cells (Figure 7B, lanes
10 and 11). Furthermore, the relative effect of the GU to AC
mutant was nearlyidentical tothat observed with the wild-type
BPS and PPT (Figure 7B, lane 12). In AT3 cells, over 90%
exon IIIc inclusion was maintained when either the BPS or the
PPT was ‘suboptimal’ regardless of the presence of ISE/ISS-3
(Figure 7C, lanes 1–3 and 10–12). When the BPS and PPT
were both suboptimal we noted a dramatic reduction in exon
IIIc inclusion in DT3 cells (Figure 7B, lanes 4–6). We
nonetheless noted that ISE/ISS-3 could still induce a further
decrease in exon IIIc inclusion. Although neither the presence
of a suboptimal BPS nor PPT alone was capable of inducing
exon IIIc skipping in AT3 cells, the combination of both
resulted in predominant exon IIIc skipping (Figure 7C,
lanes 4–6). However, in contrast to the results seen in DT3
cells, we noted no measurable difference between the level of
skipping in the absence or presence of wild-type ISE/ISS-3.
Thus, ISE/ISS-3 can function in a cell-type-speciﬁc manner to
promote exon IIIc skipping when the 30 splice site contains
either a suboptimal BPS or a suboptimal PPT. Of further note,
the fact that mutation of the PPT results in signiﬁcant impair-
ment of exon IIIc inclusion in AT3 cells that could be rescued
by changing the branchpoint G to an A suggests that this is
also the branchpoint used in vivo in cells that express FGFR2.
This is consistent with our previous in vitro branchpoint
mapping in HeLa cells and suggests that use of an alternat-
ive adenine branchsite upstream of this region is unlikely
to account for exon IIIc inclusion in cells that express
endogenous FGFR2-IIIc.
DISCUSSION
We performed extensive mutational analysis of the ISE/ISS-3
element in order to better understand its role in FGFR2
splicing regulation. The fact that this element displays
cell-type-speciﬁc splicing regulatory functions only in cells
that express FGFR2-IIIb (e.g. DT3 and KATO III cells) sug-
gests that factors that bind this element are centrally involved
in the regulation of cell-type-speciﬁc splicing of these exons.
Our results indicate that GU-rich sequence motifs within ISE/
ISS-3 enhance splicing of an upstream exon and repress splic-
ing of a downstream exon and are most consistent with a
model in which factors that bind ISE/ISS-3 are involved in
both activities and that the primary determinant as to whether
the element functions as an enhancer or silencer is its position
relative to a regulated exon. Several splicing regulatory fac-
tors, including Fox-1, Nova, CELF family members and SR
proteins, have been shown to have dual roles as both activators
Figure 7. ExonIIIcsilencingbyISE/ISS-3requireseitherasuboptimalBPSor
suboptimal PPT. (A) Schematic of the 30 splice site associated with exon IIIc
andthemutationsintroducedineithertheBPS(GtoA,indicatedbyanasterisk)
or the PPT(substitutionofthree Gsin placeof U).(B) The abilityof ISE/ISS-3
to reduce exon IIIc inclusion in DT3 cells as tested in minigenes derived from
pI-11-FS-IIIb Mut. Exon IIIc inclusion was determined in the absence ( )o r
presence(+) of ISE/ISS-3, or with ISE/ISS-3 containing the single GU to AC
mutation (Mut) shown in Figure 3 (GU Mut). The effect of ISE/ISS-3 was then
further determined with each possible combination involving the wild-type or
modified BPS or PPT as indicated. (C) Results using the same minigenes
transfected in AT3 cells.
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ability of these proteins to function either as enhancers or as
repressors of splicing was dependent on the position of the
corresponding binding site relative to an alternatively spliced
exon. Thus, for example, a Nova binding site that functioned
as an intronic splicing enhancer downstream of an exon
silenced splicing when repositioned within the exon (30).
Similarly, Fox-1 binding sites upstream of an ATP synthase
G subunit exon mediated exon skipping whereas they mediate
exon inclusion when positioned downstream of a ﬁbronectin
exon (33). Another recent study showed that intronic AC-rich
elements function as either ISEs or ISSs depending on their
proximity to a regulated 50 splice site, an effect likely to be
mediated by hnRNP L (34). However, the mechanisms by
which these regulators can function to activate or repress
splicingremainunclear.TheISE/ISS-3elementisofparticular
interest as it appears that splicing regulatory protein(s) that
bind it can simultaneously achieve such dual roles from a
single position in a manner that appears to be determined
by its position relative to the regulated exon. While our mini-
genes containing both exon IIIb and IIIc indicate that these
combined activities can occur on the same pre-mRNA, the fact
that activation of an upstream exon or repression of a down-
stream exon by ISE/ISS-3 can occur independently suggests
that these activities are not necessarily directly functionally
coupled. Using RNA afﬁnity chromatography, we have thus
far identiﬁed TLS/FUS, KSRP and FBP as proteins that bind
the wild-type, but not the 50 AC mutant, ISE/ISS-3 sequence.
However, using co-transfection experiments, we have thus far
not been able to demonstrate that any of these proteins alone
can promote exon IIIb inclusion or exon IIIc silencing. There-
fore, further studies are needed to determine whether addi-
tional factors that bind the element are required for its
function, or whether post-translational modiﬁcations may
inﬂuence the ability of these proteins to modulate splicing.
Additional mutational analysis was facilitated by the devel-
opment of a ﬂuorescent splicing reporter assay that allowed us
to directly determine the function of ISE/ISS-3 using green
ﬂuorescence. Using ﬂuorescent reporter minigenes we initially
determined that highly conserved GU-rich sequences in ISE/
ISS-3, in particular those in the 50 end of the element, are
essential for its sequence-speciﬁc splicing regulatory activity.
Using this ﬂuorescent reporter, we screened a set of more
discrete mutations in ISE/ISS-3 and using ﬂow cytometry
we identiﬁed a single GU to AC mutation that signiﬁcantly
impaired its function. Interestingly, we noted an excellent
correlation between the MFI in pooled stably transfected
cells and the level of inclusion of a heterologous exon as
determined by RT–PCR. This feature, whereby ﬂuorescence
can directly assay the ability of an intronic element to regulate
splicing indicates its potential for broader use in studies of
splicing regulation of other transcripts and regulatory ele-
ments. Similar to our use here, ﬂow cytometry can be used
in conjunction with mutational analysis to characterize other
ISEs. Furthermore, a system such as that described here should
facilitate systematic identiﬁcation of sequence motifs that can
function as ISEs through screening of randomized sequence
libraries. Of note, a recent publication used a ﬂuorescent
reporter system and sequence libraries to identify sequences
that function as ESSs in living cells and was used to identify
conserved motifs that mediate exon skipping (35).
We previously demonstrated that exon IIIc silencing is
facilitated by the highly atypical use of a guanine as the prim-
ary branch nucleotide and suggested that this may indicate that
its silencing is effected during the second step of splicing (19).
Although splice site selection is believed to generally be regu-
lated at early steps in spliceosome assembly, the recent
demonstration that the Drosophila splicing factor SXL can
silence splicing at the second step of splicing in vitro has
set a precedent for regulation of splicing after the ﬁrst step
(10,36). However, the results presented here argue strongly
against this possibility for FRFR2 exon IIIc. We found that the
effect of each branchsite nucleotide on exon IIIc inclusion in
transfected DT3 cells correlated with the efﬁciency of the ﬁrst,
but not second, step of splicing in KATO III extracts. Addi-
tionally, while the ability of ISE/ISS-3 to repress exon IIIc
splicing involves a suboptimal BPS in its native context, it can
also repress exon IIIc containing an optimal BPS and a sub-
optimal PPT. Whereas the branchsite nucleotide and the 30
splice site YAG clearly play a role in the efﬁciency of the
second step of splicing, the PPT does not appear to inﬂuence
splicing efﬁciency after the ﬁrst step of splicing (26,37,38).
Therefore, the fact that either a ‘weak’ BPS or a ‘weak’ PPT
can facilitate cell-type-speciﬁc exon IIIc silencing is further
evidence that this regulation does not involve the second step.
These ﬁndings also lend some insight into the mechanism
through which ISE/ISS-3 mediates exon IIIc repression. For
example, these results suggest that the mechanism of exon IIIc
splicing repression does not interfere with recognition of spe-
ciﬁc splicing signals, but by more generally preventing exon
deﬁnition. Exon deﬁnition involves cross-exon interactions
whereby factors that bind the 50 and 30 splice site, often
assisted by factors bound at ESE elements, cooperatively
facilitate inclusion of the exon. Thus, weak splice sites at
either end of an exon can provide an opportunity for additional
auxiliary cis-elements to assemble complexes that prevent
splicing of the exon. Therefore, our results would suggest
that while a weak branchpoint is one feature of exon IIIc
that presents an opportunity for ISE/ISS-3 to silence its inclu-
sion, other sequence components (e.g. a weak 50 splice site)
thatsimilarlyimpairthe kinetics ofspliceosomeassemblymay
also facilitate its silencing. Several combinatorial models have
been proposed by which factors bound to exons (ESSs)
and introns (ISSs) cooperatively prevent exon deﬁnition.
In the case of PTB or hnRNPA1, it has been proposed that
binding sites on both sides of a regulated exon can repress
its inclusion either through protein–protein interactions by
proteins bound on both sides of the exon that ‘loop out’ the
exon or create a ‘zone of silencing’ that sequesters the exon
and prevents its splicing (39,40). ESSs within exon IIIc have
previously been described that may cooperate with ISE/ISS-3
to assemble a repressor complex that prevents exon IIIc inclu-
sion (18). How the same protein complex assembled on ISE/
ISS-3 enhances exon IIIb inclusion will also require further
study. While these proteins may directly promote spliceosome
assembly on exon IIIb, an alternative model is that they may
interfere with factors bound at upstream ISS elements that
have previously been shown to otherwise silence exon IIIb
exon deﬁnition (41). Further characterization of factors that
associate with ISE/ISS-3 should allow us to further investigate
the mechanisms by which it participates in these dual
regulatory activities.
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